Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Approaches to prophylaxis and therapy.

Dominique Dormont1

  • 1Service de Neurovirologie, CEA, CRSSA, EPHE, Univeristé Paris XI, Fontenay-aux-Roses, France.

British Medical Bulletin
|October 3, 2003
PubMed
Summary

No cure exists for transmissible spongiform encephalopathies (TSEs), as brain damage is irreversible by the time symptoms appear. Early diagnosis is crucial for preventing neurodegeneration in TSEs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulation of indoleamine-2,3-dioxygenase expression and activity by HIV-1 in human macrophages.

Fundamental & clinical pharmacology·2009
Same author

Increase of monoamine oxidase-B activity in the brain of scrapie-infected hamsters.

Neurochemistry international·2008
Same author

Comparative effects of two type I interferons, human IFN-alpha and ovine IFN-tau on indoleamine-2,3-dioxygenase in primary cultures of human macrophages.

Fundamental & clinical pharmacology·2007
Same author

Using budding yeast to screen for anti-prion drugs.

Biotechnology journal·2006
Same author

Characterization of human monocyte-derived microglia-like cells.

Glia·2006
Same author

Preclinical metabolic changes in mouse prion diseases detected by 1H-nuclear magnetic resonance spectroscopy.

Neuroreport·2005

Area of Science:

  • Neuroscience
  • Pathology

Background:

  • Human transmissible spongiform encephalopathies (TSEs) lack effective cures or stabilization strategies.
  • Neurodegeneration in TSEs is advanced by clinical onset, rendering it untreatable.
  • Preclinical diagnosis is essential for potentially preventing or delaying neurodegeneration.

Purpose of the Study:

  • To review the current state of experimental therapeutics for TSEs.
  • To highlight the link between understanding TSE pathogenesis and developing effective treatments.

Main Methods:

  • Review of experimental treatment strategies for TSEs.
  • Analysis of pathogenesis data from rodent TSE models.
  • Discussion of high-throughput screening platforms for drug discovery.

Main Results:

  • Significant neurodegeneration occurs before clinical symptoms are detectable in TSEs.
  • Prion protein (PrPSc) accumulation and neuropathological lesions are severe at disease onset.
  • Current diagnostic tests cannot detect TSE infections during the preclinical phase.

Conclusions:

  • Therapeutic interventions for TSEs are limited due to advanced neurodegeneration at clinical presentation.
  • Effective TSE therapy development hinges on a deeper understanding of disease pathogenesis and the causative agent.
  • Increased research efforts are focused on experimental TSE therapies, driven by the emergence of variant Creutzfeldt-Jakob disease (vCJD).

Related Experiment Videos